Evidence map›Paper›PMID 24423923›Full record

ArticleBritish journal of cancer2014

Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats.

M J Walters, K Ebsworth, R D Berahovich, M E T Penfold, S-C Liu, R Al Omran, M Kioi, S B Chernikova, D Tseng, E E Mulkearns-Hubert and 12 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 86 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Trial
  4. Review
  5. The GPCR Connection: Linking Alzheimer's Disease and Glioblastoma.Journal of cellular and molecular medicine · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications.International journal of biological sciences · 2023
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 1 country.

M J WaltersChemoCentryx Inc., 850 Maude Ave, Mountain View, CA 94043, USA.
K EbsworthChemoCentryx Inc., 850 Maude Ave, Mountain View, CA 94043, USA.
R D BerahovichChemoCentryx Inc., 850 Maude Ave, Mountain View, CA 94043, USA.
M E T PenfoldChemoCentryx Inc., 850 Maude Ave, Mountain View, CA 94043, USA.
S-C LiuDepartment of Radiation Oncology, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, USA.
R Al OmranDepartment of Radiation Oncology, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, USA.
M KioiDepartment of Radiation Oncology, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, USA.
S B ChernikovaDepartment of Radiation Oncology, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, USA.
D TsengDepartment of Radiation Oncology, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, USA.
E E Mulkearns-HubertDepartment of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
M SinyukDepartment of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
R M Ransohoff1] Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA [2] Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA.
J D Lathia1] Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA [2] Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA.
J KaramchandaniDepartment of Pathology, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, USA.
H E K KohrtDepartment of Medicine, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, USA.
P ZhangChemoCentryx Inc., 850 Maude Ave, Mountain View, CA 94043, USA.
J P PowersChemoCentryx Inc., 850 Maude Ave, Mountain View, CA 94043, USA.
J C JaenChemoCentryx Inc., 850 Maude Ave, Mountain View, CA 94043, USA.
T J SchallChemoCentryx Inc., 850 Maude Ave, Mountain View, CA 94043, USA.
M MerchantDepartment of Neurology, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, USA.
L RechtDepartment of Neurology, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, USA.
J M BrownDepartment of Radiation Oncology, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, USA.
Stanford University · USChemoCentryx (United States) · USCleveland Clinic Lerner College of Medicine · USCase Western Reserve University · US

Funding

Development of Clinical Strategies to Prevent GBM Recurrences After RadiotherapyR01CA149318 · NCI · STANFORD UNIVERSITY · PI BROWN, JOHN MARTIN · 2011 to 2015
$2.4M
Novel adhesion mechanisms in glioblastoma stem cellsR01NS083629 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI LATHIA, JUSTIN D. · 2013 to 2017
$1.7M
Microenvironmental regulation of the cancer stem cell phenotype by integrin a6R00CA157948 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI LATHIA, JUSTIN D. · 2012 to 2014
$725k
Microenvironmental modulation as a result of glioma therapyK99CA157948 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI LATHIA, JUSTIN D. · 2011 to 2011
$99k
NCI NIH HHS CA157948NCI NIH HHS K99 CA157948NCI NIH HHS R00 CA157948NCI NIH HHS R01 CA149318NCI NIH HHS R01CA149318NINDS NIH HHS NS083629NINDS NIH HHS R01 NS083629
6 · The paper itself

Abstract

backgroundIn experimental models of glioblastoma multiforme (GBM), irradiation (IR) induces local expression of the chemokine CXCL12/SDF-1, which promotes tumour recurrence. The role of CXCR7, the high-affinity receptor for CXCL12, in the tumour's response to IR has not been addressed.

methodsWe tested CXCR7 inhibitors for their effects on tumour growth and/or animal survival post IR in three rodent GBM models. We used immunohistochemistry to determine where CXCR7 protein is expressed in the tumours and in human GBM samples. We used neurosphere formation assays with human GBM xenografts to determine whether CXCR7 is required for cancer stem cell (CSC) activity in vitro.

resultsCXCR7 was detected on tumour cells and/or tumour-associated vasculature in the rodent models and in human GBM. In human GBM, CXCR7 expression increased with glioma grade and was spatially associated with CXCL12 and CXCL11/I-TAC. In the rodent GBM models, pharmacological inhibition of CXCR7 post IR caused tumour regression, blocked tumour recurrence, and/or substantially prolonged survival. CXCR7 expression levels on human GBM xenograft cells correlated with neurosphere-forming activity, and a CXCR7 inhibitor blocked sphere formation by sorted CSCs.

conclusionsThese results indicate that CXCR7 inhibitors could block GBM tumour recurrence after IR, perhaps by interfering with CSCs.

Indexed as

AnimalsBrain NeoplasmsChemokine CXCL11Chemokine CXCL12GlioblastomaHumansMiceMice, NudeNeoplasm Recurrence, LocalNeoplastic Stem CellsRatsRats, Sprague-DawleyReceptors, CXCRChemokine CXCL11Chemokine CXCL12Receptors, CXCR

Identifiers

PMID24423923
PMCPMC3950859
OpenAlexW2024727509

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.